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Abstract
Heme oxygenase-1 (HO-1), also known as heat shock protein 32 (hsp-32) is a stress-induced cytoprotective protein. The present 
investigation evaluated the capacity of HO-1 to reduce the incidence of reperfusion-induced ventricular fibrillation (VF) and infarct size.
HO-1 transgenic (Tg) mice were generated using a rat HO-1 genomic transgene. Isolated mouse hearts obtained from Tg and non-trans-
genic (NTg) groups were exposed to 20 min. of global ischemia and 120 min. of reperfusion. Epicardial electrocardiogram was recorded
to monitor the incidence of reperfusion-induced VF and at the end of the reperfusion period, detection of HO-1 by immunohistochem-
istry and measurement of infarct size using the tetrazolium chloride method were carried out. Results shown here provide additional
support for cardioprotective effects of HO-1 as demonstrated by the reduced infarct size. Moreover, overexpression of the HO-1 
efficiently reduced the incidence of ischemia/reperfusion induced VF in HO-1 Tg mice.
Keywords: ischemia/reperfusion • isolated mouse hearts • HO-1 transgenic • HO-1 knockout
J. Cell. Mol. Med. Vol 14, No 9, 2010 pp. 2268-2272
© 2010 The Authors
Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
doi:10.1111/j.1582-4934.2010.01142.x
Introduction
In the past decades, extensive characterization of heme oxyge-
nase-1 heat shock protein 32 (HO-1; hsp-32) and its isozymes
have been conducted. HO-1 may be induced by various stressors
such as ultraviolet irradiation, hypoxia and ischemia, providing
protection against tissue damage [1, 2]. The enzymatic function
of HO-1 is to degrade heme, which produces iron, the antioxidant
bilirubin and the endogen carbon monoxide (CO). Enhanced levels
of these degradation products were shown to play a major role in
the cytoprotective effects of HO-1 [3].
Previously, experiments conducted in our laboratory demon-
strated that low levels of HO-1 mRNA and protein along with
reduced enzyme activity correlated with poor recovery of the
ischemic/reperfused myocardium. Moreover, increased incidence
of ventricular arrhythmias and infarct size were detected in hearts
of HO-1 knockout (KO)–/– mice [4, 5]. Furthermore, Varadi et al.
demonstrated reduced infarct size and ventricular fibrillation (VF)
after the administration of CORM-3, a CO-releasing molecule [6].
To explain the cause and development of the ventricular arrhyth-
mias, a range of different mechanisms have been suggested, but
relatively few studies have investigated the mechanism(s) of VF at
the level of gene expression. As an example, the long QT 
syndrome and idiopathic VF, as currently understood, are cardiac
disorders based on mutations for genes encoding potassium
channels, which cause sudden cardiac death from ventricular
arrhythmias [7, 8]. The major objective of the present study was
to investigate the role of HO-1 on the incidence of reperfusion-
induced VF and infarct size in Tg mouse hearts.
Methods
Transgenic mice
Transgenic (Tg) mice were generated as described by Araujo et al. [9]. In
brief, CFY mouse eggs were injected with 52 kb rat HO-1 construct con-
taining 27.7 kb of the 5 upstream region, 8.3 kb of HO-1 gene and 16 kb
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of the 3 downstream region. Cloning was carried out by PCR of rat
genomic P1 library with two sets of PCR primers corresponding to the first
exon (5-GCT-TCG-GTG-GGT-TAT-CTG-CCG-TTA-T-3 and 5-CAG-TCT-
TAC-AGG-CGG-GGA-ATG-TGA-G-3), and the fifth exon of rat HO-1 gene
(5-GAG-ACG-CCC-CGA-GGA-AAA-TCC-CAG-AT-3 and 5-CCC-AAG-AAA-
AGA-GAG-CCA-GGC-AAG-AT-3). Two clones were identified as positives,
and restriction mapping showed that both of them included the same
insert. The 52 kb band was equivalent to the HO-1 gene and flanking
regions. This 52 kb fragment, including the native HO-1 gene and its 
promoter, was excised and digested with -agarase and then microin-
jected. Mice were genotyped by PCR using the set of primers specific for
rat HO-1 exon 5.
RT-PCR
RNAs were isolated from the left and right ventricles (LV and RV), and sep-
tum (about 50 mg) of mouse hearts by guanidine isothiocyanate
acid/phenol method, and 5 g of total RNA was used to synthesize first
strand cDNA by the SuperScript First-Strand Synthesis System for RT-PCR
(Invitrogen, San Diego, CA, USA). The cDNA product was amplified by PCR
with specific primers for rat HO-1 exon 5 (CCC-TTC-CTG-TGT-CTT-CCT-
TTG and ACA-GCC-GCC-TCT-ACC-GAC-CAC-A). The RT-PCR product was
separated using 1.5% agarose gel, and visualized by ethidium bromide.
Animals and heart preparation
Male wild-type, HO-1 Tg and HO-1 KO–/– mice (25–35 g) were used for
all studies. Animals received humane care in compliance with the
‘Principles of Laboratory Animal Care’ formulated by the National Society
for Medical Research and the Guide for the Care and Use of Laboratory
Animals prepared by the National Academy of Sciences and published by
the National Institute of Health (NIH Publication No. 86–23, revised
1996). Mice were anaesthetized with 80 mg/kg of pentobarbital sodium;
heparin was used as anticoagulant (intraperitoneally 1000 IU/kg). After
the anaesthesia, the chest was opened; the heart was rapidly excised and
mounted to a ‘working’ perfusion apparatus [5]. The perfusion was
established with a modified oxygenated Krebs–Henseleit buffer with the
following concentrations (in mM): 118.4 NaCl, 4.1 KCl, 2.5 CaCl2, 
25 NaHCO3, 1.17 KH2PO4, 1.46 MgCl2 and 11.1 glucose. The perfusion
buffer was previously saturated with a mixture of 95% O2 and 5% CO2,
pH 7.4 at 37C. In all experiments global ischemia was induced for 
20 min. followed by 2 hrs of reperfusion.
Registration of VF and measurement 
of cardiac function
Epicardial electrocardiograms (ECGs) were recorded throughout the exper-
imental period by two silver electrodes attached directly to the heart and
connected to a data acquisition system (ADInstruments, Powerlab, Castle
Hill, Australia). ECGs were analysed to determine the presence or absence
of VF. Hearts were considered to be in VF if an irregular undulating base-
line was apparent on ECGs. If the duration of VF was longer than 2 min.,
the VF was defined as sustained VF, otherwise the VF was non-sustained.
If VF developed and the sinus rhythm did not spontaneously return within
the first 2 min. of reperfusion, hearts were electrically defibrillated by a
defibrillator using two silver electrodes and 15 V square-wave pulse of 
1 msec. duration and reperfused [5].
Measurement of infarct size
Infarct size was measured, at the end of each experiment, with 10 ml of 1%
triphenyl tetrazolium chloride (TTC) solution in phosphate buffer (Na2HPO4
88 mM, NaH2PO4 1.8 mM) injected via the side arm of the aortic cannula
then stored at –70C for later analysis. Frozen hearts were sliced trans-
versely in a plane perpendicular to the apico-basal axis into 1–2-mm-thick
sections, weighted, blotted dry, placed in between microscope slides and
scanned on a Hewlett-Packard Scanjet 5p single pass flat bed scanner
(Hewlett-Packard, Palo Alto, CA, USA). Using the NIH Image 1.61 image
processing software, each digitized image was subjected to equivalent
degrees of background subtraction, brightness and contrast enhancement
for improved clarity and distinctness. Infarct zones of each slice were
traced and the respective areas were calculated in terms of pixels. The
areas were measured by computerized planimetry software and these
areas were multiplied by the weight of each slice, then the results summed
up to obtain the weight of the risk zone (total weight of the LV, mg) and the
infarct zone (mg). Infarct size was expressed as the ratio, in percentage, of
the infarct zone to the risk zone [5].
Immunohistochemistry
Paraffin sections (7 m) of tissue were incubated in the presence of poly-
clonal antibody and purified liver HO-1 obtained from rats (Stress Gen
Biotech., Victoria, BC, Canada). Reactions were visualized by immunoper-
oxidase colour reaction in NTg, HO-1 Tg and HO-1 KO ischemic/reperfused
mouse myocardium. Formalin fixed tissues were paraffin embedded and 7
m sections were placed on poly-l-lysine coated glass slides (Sigma, St.
Louis, MO, USA). Following deparaffinization and rehydration, samples
were used for quenching endogenous peroxidases and blocking non-spe-
cific binding sites by 3% H2O2 in normal goat serum. Sections were incu-
bated for another 2 hrs with HO-1 antibody at a dilution of 1:750 as
described in the manufacturer’s manual. After 10 min. of phosphate-
buffered solution washing, slides were incubated for additional 30 min. in
the presence of purified biotinylated anti-rabbit IgG (Vector, Burlingame,
CA, USA) at a dilution of 1:200. Slides were rewashed in phosphate-
buffered solution and incubated with peroxidase conjugated streptavidin
(Zymed, Carlsbad, CA, USA) for 30 min. followed by red colour develop-
ment using 3-amino-9-ethylcarbazole in 0.1 M of acetate buffer (pH 5.2).
Sections were counterstained with Gill’s haematoxylin for 15–20 sec.,
rinsed with deionized water and dipped in 1% of lithium carbonate. After
draining off water slides were placed in oven for 30 min. at 80C, and then
covered with permount cover slips. Sections were photographed using a
Zeiss (Göttingen, Germany) light microscope.
Statistics
The data for infarct size were expressed as the mean  S.E.M. One-way
analysis of variance was first carried out to test for any differences between
the mean values of groups. If differences were established the values of
NTg group were compared to those of HO-1 Tg, and HO-1 KO–/– groups by
multiple t-test followed by Bonferroni test. Because of the non-parametric
distribution of the incidence of VF (sustained and non-sustained), the chi-
square test was used to compare individual groups. A change of P  0.05
was considered to be statistically significant.
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Results
The expression of the rat HO-1 transgene was confirmed in the
mouse heart at mRNA levels. Total RNA was isolated from the
non-ischemic LV, RV and septum (S) of Tg and NTg littermates
and RT-PCR was carried out using a specific primer correspon-
ding to the rat HO-1. Figure 1 shows the intense rat HO-1 signal
detected in the LV, RV and S in hearts obtained from HO-1 Tg ani-
mals (Fig. 1. upper part, right), while the signal was absent in
RNA samples obtained from NTg mice (Fig. 1, upper part, left).
The results were expressed as relative ratio and shown in Fig. 1
(lower part).
To confirm the HO-1 expression at protein level, cardiac sam-
ples were obtained from NTg, HO-1 Tg and HO-1 KO mouse
myocardium and immunohistochemical staining was performed.
Figure 2A shows that HO-1 in NTg myocardium was stained in
blue, the staining was intensified in Tg myocardium, and was
diminished in KO myocardium after 20 min. of ischemia followed
by 120 min. of reperfusion.
The results of the infarct size studies are also presented in 
Fig. 2A. We have detected a significantly reduced infarct size in
hearts obtained from HO-1 Tg mouse in comparison with the NTg
control value of 37  4% versus 20  6% (*P  0.05). In agree-
ment with our previous study the infracted area was markedly
increased in the HO-1 KO hearts to 47  5% (*P  0.05) in com-
parison with NTg group.
Figure 2B shows the incidence (%) of reperfusion-induced VF
as total (sustained and non-sustained) and sustained VF in NTg,
HO-1 Tg and HO-1 KO–/– mouse groups. Thus, the incidence of
reperfusion-induced total and sustained VF (Fig. 2B) was signifi-
cantly reduced in the HO-1 Tg group to 25% (*P  0.05) and 8%
(*P  0.05) in comparison with the NTg control values of 92%
and 83%, respectively. In hearts obtained from HO-1 KO–/– mice
(Fig. 2B), the incidence of reperfusion-induced total and sustained
VF were 100% and 100%, respectively, showing the important role
of HO-1 in arrhythmogenesis.
Fig. 1 The detection of rat HO-1 transgene by PCR in the mouse
myocardium. Total RNA was obtained from mouse LV, RV and septum (S),
respectively, and was used to synthesize first strand cDNA. Rat HO-1 was
amplified by PCR exon 5-specific primer and visualized with ethidium bro-
mide as a 166 bp band by agarose gel electrophoresis in the mouse heart.
Representative pictures of HO-1 RT-PCR results are shown in the upper
part of the figure, the specific bands of Tg mouse myocardium depicted in
the upper right, while the results of NTg littermates shown in the upper left.
Lower part of the figure shows the calculated values of HO-1 Tg signal
intensity in NTg and Tg tissues. n  4 in each group, mean  S.E.M., 
*P  0.05, comparisons were made to the corresponding NTg values.
Fig. 2 Infarct size and HO-1 staining in isolated NTg, Tg and HO-1 KO mouse
hearts subjected to 20 min. of normotermic global ischemia followed by 
120 min. of reperfusion. Infarct is represented by white area surrounding by
the living red tissues (A, right lower part). Mean  S.E.M., *P  0.05 com-
pared to the NTg control values. Immunochemical localization of HO-1 is
stained by blue in NTg, Tg and KO myocardium (A, left lower part). (B)
Representative ECG records corresponding to sinus rhythm and VF, respec-
tively, are given in the upper part of (B). The incidence (%) of total (open bars)
and sustained (hatched bars) reperfusion-induced VF in isolated NTg, Tg and
KO mouse hearts are shown in the lower part of (B). The incidence of reperfu-
sion-induced VF was registered, and comparisons were made to the values of
NTg group. n  12 in each group, *P  0.05. Because of the non-parametric 
distribution in the incidence of total and sustained VF, the chi-square non-para-
metric test was used to compare individual groups.
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Discussion
Myocardial ischemia/reperfusion (I/R) induced damage is one of the
leading causes of morbidity and mortality in industrialized societies.
Consequently, extensive effort has been devoted to characterization
of the underlying mechanisms contributing to this spectrum of 
disorders and to develop new strategies for avoiding I/R-induced
damage. Increasingly, this field of medical research is exploring
approaches involving modification of the regulation of genes con-
tributing to cardiovascular homeostasis. It has been shown by other
investigators that induction of various survival genes has the capa-
bility to reduce the I/R-induced damage and enhance the viability of
the myocardium after I/R [10]. Consistent with this observation, the
reduction of the levels of various cell death-related proteins also
protects the heart from I/R-induced injury.
Other studies have shown that cardioprotection against I/R
may also be enhanced by changes in the levels of redox-related
and detoxifying proteins. One of the potential candidates for this
phenomenon is the HO-1 system, an essential enzyme responsi-
ble for the cleavage of heme to biliverdin, endogenous CO and
iron. Previously, we have found a reduced level of HO-1 mRNA and
protein expression in fibrillated ischemic/reperfused rat
myocardium [4]. Consistent with this observation, experiments
conducted in our laboratory demonstrated that reduced HO-1
enzyme activity ultimately led to reduced level of endogenous CO
production. In a subsequent study also in our laboratory, HO-1 KO
mice were used to demonstrate the role of HO-1 and endogenous
CO in protection against I/R-induced arrhythmias and injury [5].
These studies demonstrated that eliminating HO-1 causes a
reduced level of endogenous CO production, leading to enlarged
infarct size and poor recovery of post-ischemic cardiac function.
Furthermore, VF was detected in all of the HO-1 KO–/– hearts,
demonstrating the important role of HO-1 and endogenous CO
formation in the development of reperfusion-induced VF. These
findings led to further investigations of the crucial role of HO-1 in
the development of I/R-induced VF, in which anti-arrythmogenic
effect was studied using Tg mice overexpressing rat HO-1. Heart
tissue harvested from this Tg strain contained elevated HO-1 
levels and the animals exhibited reduced infarct size and incidence
of VF in comparison with wild-type control mice. Results of the
present investigation further confirm the cardioprotective role of
the HO-1 in ischemic/reperfused myocardium.
The endogenous HO-1/CO system can protect myocardial cells
via different signalling mechanisms against doxorubicin-induced
mitochondrial damage [11]. Thus, interventions influencing the
function of HO-1/CO signalling in connection with mitochondrial
gene expression or repression such as cytochrome oxidase B sub-
unit III and ATP synthase subunit 6 [12] should be effective in
reducing targeted mitochondrial damage related to VF-induced
sudden cardiac death. Ongoing investigations are planned to
assess the impact of the HO-1/CO system on mitochondrial gene
regulation and to clarify the involvement of mitochondrial genes or
other mechanisms in the anti-arrythmogenic effect of HO-1 sys-
tem. The results of the present study can be translated to an actual
clinical situation with some caution, if mitochondria, as the primary
energy source of the myocardium, are involved in various diseases
connected to myocardial ischemia; however, further studies need
to be done to investigate how this genomic gene (HO-1) affects the
function of the aforementioned mitochondrial genes.
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